Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-Wide Transcription Responses to Synchrotron Microbeam Radiotherapy

ABSTRACT: We hypothesized that gene expression changes in EMT6.5 tumors after Microbeam Radiotherapy (MRT) are different from those seen after broad beam (BB) at 4-48 h postirradiation. Our findings demonstrate molecular differences in the tumor response to MRT vs. BB and provide insight into the underlying mechanisms of MRT and BB.

ORGANISM(S): Mus musculus

PROVIDER: GSE65625 | GEO | 2015/02/05

SECONDARY ACCESSION(S): PRJNA274496

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome-Wide Transcription Responses to Synchrotron Microbeam Radiotherapy

Project description:We hypothesized that gene expression changes in EMT6.5 tumors after Microbeam Radiotherapy (MRT) are different from those seen after broad beam (BB) at 4-48 h postirradiation. Our findings demonstrate molecular differences in the tumor response to MRT vs. BB and provide insight into the underlying mechanisms of MRT and BB. Total RNA obtained from isolated EMT6.5 tumours irradiated by MRT or BB at 4, 24 or 48 hours post-irradiation compared to unirradiated control tumours.

2015-02-05 | E-GEOD-65625 | biostudies-arrayexpress

Superiority of spatially fractionated over broad beam synchrotron radiotherapy

Project description:Transcriptomic response of tumoral and normal brain tissue, treated with the MRT irradiation or the BB irradiation, after 6 h, 48 h, 8 days, 15 days, using Affymetrix GeneChip® Rat 230_ 2.

2018-07-01 | GSE56113 | GEO

Towards melanoma in situ vaccination with multiple ultra-narrow X-ray beams

Project description:Despite the recent progress, current treatment modalities are not able to eradicate cancer. We show that Microbeam Radiotherapy (MRT), an innovative type of Spatially Fractionated Radiotherapy, can control murine melanoma by activating the host’s own immune system. The beneficial effects are very pronounced in comparison to uniform radiotherapy, traditionally employed in the clinic. Our results displayed that MRT increased antigen presentation, activating Cytotoxic T Lymphocytes (CTLs) which are essential to MRT’s treatment efficacy in melanoma. Depletion of CTLs abrogated treatment response. Multiplex nucleic acid hybridization technology revealed key features of lymphocyte populations such as proliferation, differentiation, and ligand-receptor interactions. In addition, CTLs were shown to be essential for locoregional metastatic control and systemic abscopal effects confirmed by activation of antigen presenting cells and CTL trafficking in the tumour-draining lymph nodes. MRT induces a robust antitumour immune response, matching the characteristics of in situ vaccination, that could be exploited to treat a variety of treatment-resistant malignancies.

2024-11-13 | GSE268311 | GEO

Combined external beam radiotherapy (photon or carbon) and 131I-MIP-1145 (benzamide) endoradiotherapy in syngeneic B16F10 mouse tumor model

Project description:Subcutaneous B16F10 tumors in the right hind limb of C57BL/6 mice were treated with 5 daily fractions of external beam radiotherapy (8 Gy photon or 5 Gy carbon per fraction), a single fraction of 13.3 MBq 131Iodine-labelled benzamide-derivative MIP-1145 intravenously or a combination of the two. Untreated tumors served as controls. Mice were sacrificed and tumor tissue collected for expression profiling 5 days after endoradiotherapy of 1 week after the last fraction of external beam radiotherapy.

2023-12-08 | E-MTAB-6514 | biostudies-arrayexpress

Transcription profiling by array to investigate the effect of combined external beam radiotherapy (photon or carbon) and 131I-Cetuximab endoradiotherapy in A431 xenograft tumors in mice

Project description:Subcutaneous A431 tumors in the right hind limb of NCr nu/nu mice were treated with 5 daily fractions of external beam radiotherapy (2 Gy photon or 1 Gy carbon per fraction), a single fraction of 7.2 MBq 131Iodine-labelled Cetuximab intravenously or a combination of the two. Untreated tumors served as controls. Mice were sacrificed and tumor tissue collected for expression profiling 5 days after endoradiotherapy of 1 week after the last fraction of external beam radiotherapy.

2023-12-08 | E-MTAB-6515 | biostudies-arrayexpress

Gene expression profiles of primary tumors with radiotherapy and lung metastases in mouse squamous cell carcinoma model.

Project description:To examine whether the local carbon ion radiotherapy affects the characteristics of the metastatic tumors, the expression profiles of the primary tumors and the lung metastases were studied in a mouse squamous cell carcinoma model by applying local radiotherapy with no irradiation (negative control), gamma-ray irradiation (reference beam), and carbon-ion irradiation. Keywords: mouse, squamous cell carcinoma, primary tumor, lung metastases, radiotherapy, carbon ion, gamma ray A highly metastatic mouse squamous cell carcinoma NR-S1 was implanted into the hind leg of synergetic C3H/HeNrs mice and irradiated with 5 Gy of carbon ion beam. 8 Gy of gamma ray was used as a reference beam. At 2 weeks after the irradiation, the lung tissue was sampled. In order to collect samples of primary tumors, the tumors were implanted in other mice and irradiated in the same manner, and the primary tumors were collected at 1 week after the irradiation. The tumor cells of the primary and metastatic tumors were collected by laser microdissection, and oligonucleotide microarray analysis of the irradiated primary tumors and the metastatic tumors were all performed in comparison to the non-irradiated primary tumor by two-color methods.

2009-04-22 | E-GEOD-9305 | biostudies-arrayexpress

Gene expression profiles of primary tumors with radiotherapy and lung metastases in mouse squamous cell carcinoma model.

2009-04-23 | GSE9305 | GEO

Mus musculus

Project description:Genome-Wide Transcription Responses to Synchrotron Microbeam Radiotherapy

| PRJNA274496 | ENA

Genetic Predictors of Adverse Radiotherapy Effects (Gene-PARE)

Project description:<p>The goal of this study was to identify SNPs and CNPs that are associated with development of normal tissue toxicities resulting from radiotherapy for prostate cancer. The study population includes approximately 1,400 men treated with brachytherapy, external beam radiation therapy, or a combination of the two treatments, and assessed for adverse effects at baseline and following radiotherapy. Three toxicity endpoints were investigated using a two-stage GWAS approach: urinary morbidity, rectal bleeding and erectile dysfunction. The study sample was split into a discovery set (N=367) and a replication set (N=417), and an additional 647 samples, which were not part of this original cohort, were also included as an independent replication set. The replication set was developed via collaboration developed under the framework of the Radiogenomics Consortium (RGC).</p> <p>The long-term goal of this project, and other radiogenomics projects lead by the RGC, is two-fold: 1) Develop an assay capable of predicting which cancer patients are most likely to develop radiation injuries resulting from treatment with a standard RT protocol, and 2) Obtain information to assist with the elucidation of the molecular pathways responsible for radiation-induced normal tissue toxicities. These studies focus on multiple cancer types including prostate, breast, lung, and head and neck cancers.</p>

| phs000772 | dbGaP

Rattus norvegicus

Project description:Transcriptomic analysis of early response of rat brain orthotopic tumors after synchrotron microbeam irradiation (MRT)

| PRJNA217709 | ENA